Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207336 | 0.71 | MEN1 (0.30) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL1740246 | 0.71 | GRK6 (0.33) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL5500863 | 0.68 | — | — | |
| SCHEMBL3098907 | 0.65 | — | — | |
| SCHEMBL11622731 | 0.62 | MEN1 (0.40) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL28912687 | 0.62 | GRK6 (0.41) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL29419088 | 0.60 | ALDH1A1 (0.32) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL123760 | 0.60 | ALDH1A1 (0.32) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL5613285 | 0.60 | ALDH1A1 (0.32) | MEN1USP2PPARGKMT2AKEAP1 | |
| SCHEMBL1162635 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | claimed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | claimed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | claimed |
| CN-109563094-B | (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2022-03-18 | — | — | CN | claimed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | claimed |
| EP-3386511-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-05-12 | — | — | EP | claimed |
| US-10874672-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | claimed |
| EP-2915804-B1 | NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-03-27 | — | — | EP | claimed |
| EP-3366685-A1 | TRYPTOLINE DERIVATIVES HAVING KINASE INHIBITORY ACTIVITY AND USES THEREOF | X-Chem, Inc. (US) | 2018-08-29 | — | — | EP | claimed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | claimed |
| EP-0587193-B1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO LTD (JP) | 1997-01-02 | — | — | EP | claimed |
| EP-0748805-A1 | Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them | TANABE SEIYAKU CO., LTD. (JP) | 1996-12-18 | — | — | EP | claimed |
| EP-0589484-B1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO LTD (JP) | 1996-10-16 | — | — | EP | claimed |
| US-5472984-A | 1,2-ethanediol derivative and salt thereof and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-12-05 | — | — | US | claimed |
| EP-0383281-B1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO LTD (JP) | 1994-08-17 | — | — | EP | claimed |
| EP-0589484-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | claimed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | claimed |
| EP-0587194-A1 | 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | claimed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | claimed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | MEN1 3606/4885USP2 1879/4885PPARG 1469/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | MEN1 3606/4885USP2 1879/4885PPARG 1469/4885 |
| US-10874672-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | MEN1 1416/4885USP2 2004/4885PPARG 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.